Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 3;11(3):75.
doi: 10.3390/ijns11030075.

Comparing DNA Isolation and Preparation Protocols for Dried Blood Spots in the Context of Genomic Newborn Screening

Affiliations

Comparing DNA Isolation and Preparation Protocols for Dried Blood Spots in the Context of Genomic Newborn Screening

Annelotte J Duintjer et al. Int J Neonatal Screen. .

Abstract

Due to rapid technical advancements and increasing cost-effectiveness, the potential application of next-generation sequencing (NGS) in newborn screening (NBS) has raised great interest worldwide. Genomic NBS offers the possibility to improve current NBS programs when applied as follow-up tier, and, as first-tier, allows for inclusion of conditions lacking a detectable biomarker for conventional NBS. Obtaining enough high-quality DNA from typically limited dried blood spot (DBS) material to meet NGS requirements can be challenging. Selecting a DNA isolation method for genomic NBS requires balancing technical performance and laboratory feasibility with optimal cost-effectiveness. Ten DNA isolation protocols, including two column-based, five lysis-based, and three semi-automated magnetic bead-based protocols, were evaluated on technical outcomes and performance in targeted amplicon sequencing. Additionally, estimated costs, hands-on time, turnaround time, scalability, and plastic footprint were assessed. Although technical outcomes, including yield, purity, and molecular weight, differed between methods, qualitative results in amplicon sequencing, as defined by read output, mapping, and coverage depth, were found sufficient and comparable for various protocols. In conclusion, both technical requirements and operational parameters are crucial when selecting a DNA isolation protocol and will depend on the NGS application as well as the NBS approach, as either first-tier or follow-up tier.

Keywords: DBS; DNA isolation; DNA preparation; NBS; NGS; dried blood spot; genomic newborn screening; newborn screening; next-generation sequencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 4
Figure 4
Sequencing performance based on yield, mapping, and coverage. DBS = dried blood spot. Comparison of amplicon sequencing performance between seven different DNA isolation protocols applied on one and two DBS punches (3.2 mm) of starting material, including the generated sequence reads in millions (A), percentage unmapped reads (B), mean read depth over target region (C) and percentage of amplicons (N total = 3003) with >30× read depth (D). The numbers above the columns correspond to the DNA isolation protocols described in Table 1. The bar reaches the median from all samples per protocol, with colors indicating different techniques used, including column-based (blue), lysis-based (orange), and magnetic bead-based (green). The dotted line depicts outcomes for the GIAB control sample.
Figure 1
Figure 1
DNA yield and A260/A280 ratio. DBS = dried blood spot. Comparison of DNA yield (ng) (A) and A260/A280 (B) ratio between ten different DNA isolation protocols using one, two, and three DBS punches (3.2 mm). The dotted line depicts the optimal A260/A280 ratio (B) with a 10% interval around it in grey. The numbers above the columns correspond to the DNA isolation protocols as described in Table 1. The median and range for the measurements per protocol are depicted by the bars, with colors indicating different techniques used, including column-based (blue), lysis-based (orange), and magnetic bead-based (green).
Figure 2
Figure 2
Mean DNA yield with increasing number of DBS punches. DBS = dried blood spot. Comparison of the mean DNA yield (ng) and 95% CI observed with increasing numbers of DBS punches (3.2 mm) used as starting material. The dotted line represents a hypothetical function if the yield from two and three DBS punches increased in direct proportion to the yield from one DBS punch. The colors indicate different techniques used, including column-based (blue), lysis-based (orange), and magnetic bead-based (green).
Figure 3
Figure 3
Molecular weight of isolated DNA from one DBS punch. DBS = dried blood spot. The analysis was performed with the Femto Pulse System on DNA isolated from one DBS punch (3.2 mm). For each DNA isolation protocol, results from two different donor samples are presented.

References

    1. Therrell B.L., Padilla C.D., Borrajo G.J.C., Khneisser I., Schielen P., Knight-Madden J., Malherbe H.L., Kase M. Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023) Int. J. Neonatal Screen. 2024;10:38. doi: 10.3390/ijns10020038. - DOI - PMC - PubMed
    1. Chan K., Puck J.M. Development of population-based newborn screening for severe combined immunodeficiency. J. Allergy Clin. Immunol. 2005;115:391–398. doi: 10.1016/j.jaci.2004.10.012. - DOI - PubMed
    1. van der Spek J., Groenwold R.H., van der Burg M., van Montfrans J.M. TREC Based Newborn Screening for Severe Combined Immunodeficiency Disease: A Systematic Review. J. Clin. Immunol. 2015;35:416–430. doi: 10.1007/s10875-015-0152-6. - DOI - PMC - PubMed
    1. Borte S., von Dobeln U., Fasth A., Wang N., Janzi M., Winiarski J., Sack U., Pan-Hammarstrom Q., Borte M., Hammarstrom L. Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR. Blood. 2012;119:2552–2555. doi: 10.1182/blood-2011-08-371021. - DOI - PubMed
    1. Taylor J.L., Lee F.K., Yazdanpanah G.K., Staropoli J.F., Liu M., Carulli J.P., Sun C., Dobrowolski S.F., Hannon W.H., Vogt R.F. Newborn blood spot screening test using multiplexed real-time PCR to simultaneously screen for spinal muscular atrophy and severe combined immunodeficiency. Clin. Chem. 2015;61:412–419. doi: 10.1373/clinchem.2014.231019. - DOI - PMC - PubMed

LinkOut - more resources